Your Source for BioScience Venture Capital Data
  • SEARCH THE OnBioVC DATABASE:

  • OnBioVC NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • Photobucket

  • FDA Registered Contract Manufacturer

Cleave Biosciences (Burlingame, CA) a preclinical-stage pharmaceutical company focused on small molecules for oncology, closed a $42M Series A financing. Participants include US Venture Partners, 5AM Ventures, Clarus Ventures, OrbiMed Advisors and Astellas Venture Management.

Catabasis Pharmaceuticals (Cambridge, MA) a clinical-stage biopharmaceutical company focused on fatty acid conjugated compounds for severe hypertriglyceridemia, diabetes, inflammatory and metabolic diseases, closed a $8M Series A financing bringing total round to $47.6M. Participants include SV Life Sciences, Clarus Ventures, MedImmune Ventures and Advanced Technology Ventures.

NanoString Technologies (Seattle, WA) a commercial-stage cell assay device company focused on direct digital detection for gene expression analysis, closed $20M Series D financing. Participants include General Electric, BioMed Ventures, Clarus Ventures, Draper Fisher Jurvetson and OVP Venture Partners.

Restoration Robotics (Mountain View, CA) a clinical-stage medical device company focused on computer assisted image-guidance for hair follicle harvesting, closed a $41M Series C financing. Participants include Clarus Ventures, Sutter Hill Ventures, Alloy Ventures and Interwest. Thanx for your patience as we catch-up.

TetraLogic Pharmaceuticals (Malvern, PA) a clinical-stage pharmaceutical company developing novel small molecule drugs to treat cancer, closed a $6M Series C financing bringing the total round to $43M. Participants include Nextech Invest, Clarus Ventures, Hatteras Venture Partners, Pfizer Venture Investments, HealthCare Ventures, Latterell Venture Partners, Novitas Capital, Quaker BioVentures, Vertical Group and Amgen Ventures.

TetraLogic Pharmaceuticals (Malvern, PA) a clinical-stage biopharmaceutical company developing novel small molecule drugs to treat cancer, closed a $23M Series C financing. Participants include Clarus Ventures, Hatteras Venture Partners, Pfizer Venture Investments, HealthCare Ventures, Latterell Venture Partners, Novitas Capital, Quaker BioVentures, The Vertical Group and Amgen Ventures.

Pearl Therapeutics (Redwood City, CA) a clinical-stage small molecule company focused on combination therapy for chronic obstructive pulmonary disease, closed a $69M Series C financing. Participants include Vatera Healthcare Partners, Clarus Ventures, New Leaf Venture Partners and 5AM Ventures.

Tyrx (Monmouth Junction, NJ) a commercial-stage drug:device combo company focused on a dissolving antibacterial biocompatible mesh envelope to house implanted devices such as pacemakers and defibrillators, closed a $16M Series C financing. Participants include HLM Venture Partners, Clarus Ventures and Pappas Ventures.

TetraLogic Pharmaceuticals (Malvern, PA) a preclinical-stage small molecule company focused on apoptosis and necrosis modulation for potential cancer, cardiovascular, neurological and ophthalmic disease treatment, closed a $32M Series C financing. Participants include Clarus Ventures, Hatteras Venture Partners, Amgen Ventures, HealthCare Ventures, Latterell Venture Partners, Novitas Capital, Quaker BioVentures and Vertical Group.

FerroKin Biosciences (San Carlos, CA) a preclinical-stage biopharmaceutical company focused on iron chelator for treatment of anemia, closed a $12M Series B financing. Participants include Clarus Ventures, Burrill & Co., Celegene, MP Healthcare Venture Management and Healthcap Ventures.

Oxford Immunotec (United Kingdom) a commercial-stage molecular diagnostic company focused on an vitro test for the diagnosis of active and latent tuberculosis infection, closed a $26M Series D financing. Participants include New Leaf Venture Partners, Kaiser Permanente Ventures, Clarus Ventures, Wellington Partners, National Technology Enterprises Company, Spark Ventures, DFJ Esprit, Oxford University and Dow Chemical.

Catabasis Pharmaceuticals (Cambridge, MA) a preclinical-stage company focused on lipid mediators for the treatment of inflammatory and metabolic diseases, closed a $39.6M Series A financing. Participants include SV Life Sciences, Clarus Ventures, MedImmune Ventures and Advanced Technology Ventures.

Pearl Therapeutics (Redwood City, CA) a clinical-stage pharma company focused on metered dose inhaler products for the treatment of COPD and asthma, closed a $15M Series C financing. Participants include Clarus Ventures, New Leaf Venture Partners and 5AM Ventures.

« Previous Entries  Next Page »

to top of page...